• R&D
  • R&D Volition

R&D Volition2221243310
06:00 PM EST

Discover How Cutting Edge Epigenetic Technologies are Shaping The Future of Biomarker Driven Clinical Trial Design


Next-Generation Quantitative Epigenetic Immunoassay Development
In Vivo and Ex Vivo Nucleosome Profiling in Epigenetic Therapeutic Discovery
In Vitro and Clinical Nucleosome Pharmacodynamics Assays

Meet the Facilitators

The Dinner will be lead by our expert facilitators

Mark Eccleston

Chief Technology Officer VolitionRx

Terry Kelly

Chief Scientific Officer of Volition America, Chief Innovation Officer of Volition Rx Volition

White Papers

White Paper

A valuable tool from target identification to validation in clinical studies.

Empowering drug developers and scientists through a range of state-of-the-art assays for rapid epigenetic profiling in disease, model development, preclinical testing, and clinical studies –from discovery to market ready.

White Paper

Using Nu.Q® Discover to profile histone post-translational modifications following treatment with epigenetic inhibitors.

Nu.Q® Discover Cell Culture White Paper Brandi Atteberry, Dorian Parmart, Justin Cayford, Terry Kelly


More about Volition

Volition is at the forefront of epigenetic immunoassay development, contributing to the drug discovery and development cycle from in-vitro target validation to human clinical trials. Our assays, widely used in oncology and immunotherapy, focus on delivering actionable insights to streamline the entire drug development process. Nu.Q® Discover assays have been validated in preclinical PD studies tracking epigenetic modification levels in response to epigenetic inhibitors with recent data presented at AACR demonstrating a dose-dependent reduction in specific Histone PTM levels by simple liquid biopsy. Our NETosis assay measures the release of Neutrophil Extracellular Traps, aiding in the assessment of acute inflammatory conditions like sepsis and cancer. Our Ex-vivo – Synthetic Sepsis™ platform is designed to screen NETosis modulators and potential activators, providing ex-vivo human data ahead of First-in-Human (FIH) studies. For specialized requirements, we can develop new assays following CLSI development guidelines. Our R&D activities are anchored in Belgium, complemented by an innovation lab in California and offices in Texas, London, and Singapore. For more details and scientific data please visit, volition.com.


Boston Chops, 52 Temple Pl, Boston, MA 02111, United States

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

    I agree to Proventa International storing this information to reply to my query and in accordance with our Privacy Policy.
    You may unsubscribe at any time.